4basebio PLC (AIM:4BB)
London · Delayed Price · Currency is GBP · Price in GBX 510.00
+32.00 (6.69%)
At close: Mar 25, 2026
4basebio Market Cap
4basebio has a market cap or net worth of 73.98 million as of March 25, 2026. Its market cap has decreased by -48.18% in one year.
Market Cap
73.98M
Enterprise Value
63.31M
Revenue
1.78M
Ranking
n/a
PE Ratio
n/a
Stock Price
510.00
Market Cap Chart
Since February 17, 2021, 4basebio's market cap has increased from 41.57M to 73.98M, an increase of 77.96%. That is a compound annual growth rate of 11.97%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 24, 2026 | 73.98M | -22.28% |
| Dec 31, 2025 | 95.19M | -38.57% |
| Dec 31, 2024 | 154.94M | 84.96% |
| Dec 29, 2023 | 83.77M | -4.21% |
| Dec 30, 2022 | 87.45M | 15.45% |
| Dec 31, 2021 | 75.75M | 82.22% |
| Feb 17, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Avacta Group | 290.87M |
| PureTech Health | 277.10M |
| Scancell Holdings | 119.34M |
| Bioventix | 73.67M |
| Hemogenyx Pharmaceuticals | 62.83M |
| Ondine Biomedical | 55.85M |
| Faron Pharmaceuticals Oy | 49.79M |
| hVIVO | 46.61M |